An Investor Update from Olivier Garret, CEO, Casey Research
Isis isn't the only favorite of the "Biotech Skeptic" for 2011. In fact, he discovered two more biotech stocks that could earn you even bigger profits than Isis in 2011.
"Biotech Skeptic" Recommendation #2
This company uncovered the missing link to creating working RNAi-based therapies. Ever since this big discovery, they've been at the forefront of applying this new-frontier technology, with over 700 patents worldwide in the area of RNAi.
Beyond being brilliant researchers, they run a great business too. They're solid financially, boast an impressive collection of intellectual property, have multiple lucrative licensing deals already in place, and they're constantly growing their pipeline of RNA-based drug candidates through proprietary, co-developed, and partnership programs.
Plus they boast a squeaky-clean balance sheet. All these factors helped get this company through the "Biotech Skeptic's" screening process. In fact – he expects you'll be able to collect as much as fourfold gains within the next 36 months from this investment.
And now is the time to buy this stock – recent negative news from another company has caused a pullback in this stock's price without affecting the "Biotech Skeptic's" target price, so we're sitting on a great buying opportunity that won't last long.
"Biotech Skeptic" Recommendation #3
This company takes a different approach to creating genome-based medical breakthroughs. They're in the business of testing – using these new technologies to identify the best course of treatment on a patient-by-patient basis, based in part on the expression of certain genes.
For example, their breast cancer test determines how 21 different genes are expressed within a tumor, and use that information to predict the effectiveness of chemotherapy as well as to predict the chance of recurrence.
Recent quarterly results indicating significant worldwide increases in demand for this company's products, plus solid financials and a strong pipeline of additional products has the "Biotech Skeptic" giving this stock two thumbs up.
His recommendation is already paying off for current subscribers – a recent spike handed investors nearly 21% gains in a single day. And he believes the best is yet to come. As I finalize this to send to press, the "Biotech Skeptic's" target is still a full 77% higher than today's price. The window for getting positioned in this stock won't stay open for long.
I've shown you the "Biotech Skeptic's" track record. I've shown you how he'd handed subscribers annualized gains of 84% – with a 90% win ratio – on positions closed in 2010 (and this was while the Nasdaq is up 11% and the S&P 500 is up 7.6%, which means he's beat the Nasdaq by more than 7X and the S&P 500 by 11X in 2010).
I've even shown you his first recommendation for a breakthrough biotech stock to own in 2011.
So who is this "Biotech Skeptic," and how is he able to beat the market so handily?
The "Biotech Skeptic" is our own Alex Daley, Senior Editor of Casey's Extraordinary Technology.
Alex is a technology industry insider. He was working as a top strategist for one of the world's largest tech companies when our Managing Director David Galland met him on a six-hour cross-country flight in December 2008. He'd written one of the most successful talks for the TED conferences, and has been interviewed on breaking technology stories by CNN, CNBC, CBS World News, and BBC, among many others.
(He's is even on a first-name basis with Bill Gates!)
In addition, he's been involved in numerous startups as an advisor to venture capital companies. He's also been a trusted advisor to the CEOs and strategic planners of some of the world's largest tech companies.
Plus, he has a long history of spectacular investment successes as an angel investor.
His track record investing in public companies is equally impressive:
I could go on, as these are just a sprinkling of Alex's wins. But you get the idea.
Before David met Alex on that fateful flight, we'd been looking for someone to head up Casey's Extraordinary Technology.
We wanted someone who understood the technology for technology's sake. But we didn't just want a computer geek. We wanted a savvy investor who could tell the difference between a hot technology and a hot investment opportunity – someone who could recognize when a breakthrough technology had a business team behind it to create substantial profits.
Because it takes this combination of technology and investment savvy to spot opportunities in the tech sector for investors to collect the biggest rewards with minimum downside risk.
With his background, we knew Alex was exactly who we were looking for. Luckily for us – and for his subscribers – he was intrigued enough with what we were doing at Casey Research to give up a plum job at a world-leading tech firm and join our team.Since that time, he's consistently proven his investment savvy by picking market-beating winners for subscribers time and time again – in all types of technology stocks, including biotech.
He doesn't pick these winners by relying on pedestrian publications like the Wall Street Journal. Most of the stocks touted there would never pass his stringent criteria. And like I said, more than 99% of ALL tech stocks fail his test.
At the most basic level, Alex will tell you his criteria are designed to hone in on where he can "buy growth at a reasonable price."He does this by identifying:
Once a handful of companies have made it through Alex's rigorous screening process... he picks the ones he believes have the biggest market-changing technologies, and recommends them to Casey's Extraordinary Technology subscribers.
Now you can get access to all of Alex's recommendations in Casey's Extraordinary Technology, risk-free for the next 90 days.
This includes "The Three Best Biotech Stocks for 2011" --
Plus, you get monthly analyses and in-depth research on emerging tech-sector investing opportunities.
In the monthly Casey's Extraordinary Technology advisory service, you'll discover the new technologies on the cutting edge – technologies that will soon be part of our everyday lives. (Just think – Google didn't exist before 1996, and now it's a household name and even a new verb!) You'll meet the people and companies bringing these technologies to market. And you'll discover which do (and do not) make a smart investment to grow your wealth.
You'll also get specific recommendations like...
Not only that, you'll get regular "breaking news" alerts on the current portfolio plus urgent investment opportunities – often more than one per week.
You know as well as I do, the market moves and opportunities change every trading day. When news breaks on positions in the Casey's Extraordinary Technology portfolio, you'll get an up-to-the-minute email update alerting you on what's changed, what effect it has on the investment prospects of the position, and any action you need to take.
Also, if Alex discovers a new opportunity that can't wait for the monthly issue, he will immediately shoot you an email so you don't miss out.
It's this "breaking news" service that keeps you informed as an investor and shows you how to maximize your profits on every position.
And it's all risk-free.
Here's how this works. You agree today to give Casey's Extraordinary Technology a try for the next 90 days. Once you submit your information, you'll be given access to:
All this information is yours to use and profit from risk-free for the next 90 days. So go ahead. Investigate Alex's recommendations. Make your own trades. And decide for yourself within 90 days that Alex's advice in Casey's Extraordinary Technology gives you the exact information and specific recommendations you need to collect the biggest rewards investing in biotech and the rest of the technology sector.
If at any time within those first 90 days you decide Casey's Extraordinary Technology is not a fit for your investment strategies, let us know. We'll provide you with a prompt and courteous refund of every penny you've paid.(Perhaps during those 90 days you'll get another opportunity like ArcSight, which gave Alex's subscribers 46% gains in seven days – even a small investment there would more than cover your cost of subscription!)
All you have to do now to take advantage of everything I've detailed above is to invest $199 for a risk-free, three-month "test-drive" subscription to Casey's Extraordinary Technology. (This is a 20% discount off the retail price.)
This gives you full access to all of Alex's advice, and the power to act on his current recommendations. Then, if you decide anytime within the next three months that this service isn't for you, let us know and you'll get your entire investment back.
But I'm sure once you take a look at how thoroughly researched all of Alex's recommendations are – and see his track record for yourself (closed positions are reprinted at the bottom of every issue for everyone to see) – you'll be glad you subscribed.
(And once you start profiting from his recommendations, I wager you'll be a Casey's Extraordinary Technology subscriber for life.)So why don't you give it a try?
We see it all the time in all fields of technology – big news can make stocks pop 20% or more in a single day. Alex's picks are all well positioned to see gains like these because they're solid companies with breakthrough technologies coming to market.
Any delay on your part could mean missing one or more of these opportunities.
So go ahead and try Casey's Extraordinary Technology at our risk for the next 90 days and see what opportunities it unlocks for your portfolio. I'm sure you won't regret it.Good investing,
CEO, Casey Research